Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Eastern Cooperative Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00357630 |
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well gemcitabine works in treating patients with metastatic cancer of unknown primary.
Condition | Intervention | Phase |
---|---|---|
Carcinoma of Unknown Primary Pain |
Drug: gemcitabine hydrochloride Procedure: quality-of-life assessment |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase II Protocol: Gemcitabine for Metastatic Cancer With Unknown Primary Site - Analysis of Symptom Benefit |
Estimated Enrollment: | 52 |
Study Start Date: | June 2006 |
Primary Completion Date: | February 2007 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: This is an open-label, multicenter study.
Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43, followed by 1 week of rest (course 1). For all subsequent courses, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Quality of life (QOL) and symptom response are assessed at baseline and at weeks 8, 16, and 32 (end of treatment). Questionnaires include the Memorial Symptom Assessment Scale-Short Form, Functional Assessment of Cancer Therapy-General, Pain Visual Analog Scale, and EuroQOL. Patients' perception of symptom response and perception of treatment burden are also assessed.
After completion of study treatment, patients are followed periodically for up to 3 years.
PROJECTED ACCRUAL: A total of 52 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed poorly differentiated carcinoma or adenocarcinoma of unknown primary
Must not have any of the following clinical features:
No symptom emergency at the time of study entry including, but not limited to, the following:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Study Chair: | Victor T. Chang, MD | Veterans Affairs Medical Center - East Orange |
Investigator: | Raymond S. Lord, MD | West Michigan Cancer Center |
Responsible Party: | ECOG Group Chair's Office ( Robert L. Comis ) |
Study ID Numbers: | CDR0000486704, ECOG-E5Z02 |
Study First Received: | July 26, 2006 |
Last Updated: | April 11, 2009 |
ClinicalTrials.gov Identifier: | NCT00357630 History of Changes |
Health Authority: | United States: Federal Government |
adenocarcinoma of unknown primary newly diagnosed carcinoma of unknown primary undifferentiated carcinoma of unknown primary pain |
Antimetabolites Anti-Infective Agents Neoplasms, Unknown Primary Immunologic Factors Pain Antiviral Agents Immunosuppressive Agents |
Carcinoma Radiation-Sensitizing Agents Neoplasm Metastasis Adenocarcinoma Gemcitabine Neoplasms, Glandular and Epithelial |
Antimetabolites Anti-Infective Agents Neoplasms, Unknown Primary Neoplasms by Histologic Type Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors Immunosuppressive Agents |
Antiviral Agents Pharmacologic Actions Carcinoma Neoplasms Neoplastic Processes Pathologic Processes Radiation-Sensitizing Agents Therapeutic Uses Neoplasm Metastasis Gemcitabine Neoplasms, Glandular and Epithelial |